Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVER: VERITY-BCG vs OncoTICE in NMIBC
NCT05037279Phase 3Recruiting
- Sponsor
- Verity Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- Feb 2029
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bcg vaccine in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Verity Pharmaceuticals. Primary endpoint: Recurrence Free Survival at 24 months. Started Apr 2024; status: recruiting.
02
Drugs
bcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05037279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05037279.